MAPT and Alzheimer disease: Diagnosis of AD requires the presence of both β-amyloid and tau accumulations, although the mechanisms by which they produce neurodegeneration remain unknown (van der Kant et al., 2020), and attempts to treat AD by targeting β-amyloid and tau pathology have been unsuccessful in showing conclusive cognitive improvement (Kametani and Hasegawa, 2018).